

Freedom of Information request 499-20

Request

1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?
 - Advanced oesophageal cancer
 - Myelofibrosis
2. Please provide the total number of patients treated in the last 6 months for:
 - Myelofibrosis
 - Myelofibrosis – patients over the age 65
 - Oesophageal cancer (any type)
 - Oesophageal adenocarcinoma
 - Oesophageal squamous cell carcinoma
 - Unresectable Oesophageal squamous cell carcinoma
3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with:
 - Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
 - Any other systemic anti-cancer therapy
 - Palliative care only
4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with;
 - Ruxolitinib
 - Hydroxyurea
 - Watch and wait approach
5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Response

1. Yes, both conditions are treated by NHS Borders.
2. This information is not collated electronically as patient's can be treated as an inpatient and in the community, and therefore would only be available in a patient's notes and to extract this data would require a manual trawl and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the FOI(S)A 2002 therefore we are not required to provide.
3. The table below shows the number of oesophageal squamous cell carcinoma patients treated in the past 6 months:

Treatment	Number of Patients
Platinum and Fluoropyrimidene based combination treatments	<5
Any other systemic anti-cancer therapy	<5
Palliative care only	0

4. The table below shows the number of myelofibrosis patients treated in the last 6 months:

Treatment	Number of Patients
Ruxolitinib	7
Hydroxyurea	<5
Watch and wait approach	0

5. NHS Borders does not participate in any clinical trials for oesophageal cancer.

6. NHS Borders does not participate in any clinical trials for treatment of myelofibrosis.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **499-20** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.